How private equity sponsors and physician entrepreneurs can consolidate independent IVF practices into a high-value, multi-site reproductive medicine network.
Find Fertility Clinic Platform TargetsThe U.S. fertility clinic market is an $8–9 billion industry dominated by independent physician-owned practices ripe for consolidation. With PE-backed platforms like US Fertility and CCRM already scaling, significant whitespace remains in regional markets where founder REs seek liquidity and operational support without sacrificing clinical standards.
Board-certified reproductive endocrinologists are scarce, IVF laboratory infrastructure is expensive, and employer fertility benefit contracts favor networks over solo practices. A consolidated platform unlocks shared embryology staffing, centralized billing, and contracted volume from Progyny and WINFertility that independent clinics cannot access alone.
Minimum $1.5M EBITDA
The platform anchor must generate at least $1.5M in normalized EBITDA with physician compensation adjusted to market rate to support debt service and future add-on integration costs.
Active SART Membership and Above-Average CDC ART Outcomes
Published success rates at or above national SART averages are non-negotiable. Outcome data drives patient acquisition and protects brand equity across the entire platform.
Multiple Board-Certified Reproductive Endocrinologists Under Contract
The platform clinic must employ at least two REs with enforceable non-competes, eliminating single-physician dependency before scaling through add-on acquisitions.
Fully Accredited In-House IVF Laboratory
A CLIA-certified, in-house embryology laboratory with modern equipment and documented QC protocols is essential infrastructure that add-on clinics can eventually leverage or connect to.
Geographic Proximity Without Overlap
Target clinics within 50–150 miles of the platform to enable shared embryology services and back-office consolidation without cannibalizing existing patient catchment areas.
Minimum $750K EBITDA or Breakeven with Identifiable Upside
Add-ons can be subscale if the revenue gap is attributable to fixable issues like billing inefficiency, limited service lines, or absence of employer benefit contracts.
Founder RE Willing to Sign Multi-Year Employment Agreement
Patient volume is physician-dependent. A 3–5 year employment and transition agreement with earnout provisions protects patient retention through the integration period.
Clean Regulatory History and No Adverse CDC Reports
Any prior CLIA citations, adverse SART outcomes, or unresolved malpractice claims must be resolved pre-close. Regulatory contamination in one clinic threatens the entire platform's accreditation.
Build your Fertility Clinic roll-up
DealFlow OS surfaces off-market Fertility Clinic targets with seller signals — the foundation of every successful roll-up.
Centralized Revenue Cycle and Payer Contracting
Consolidating billing operations and renegotiating insurance contracts as a multi-site network improves reimbursement rates and reduces denials across all clinics simultaneously.
Employer Fertility Benefit Platform Contracts
Securing network agreements with Progyny or WINFertility at the platform level channels guaranteed patient volume to every clinic in the portfolio, replacing inconsistent self-pay acquisition.
Service Line Expansion Across All Sites
Adding egg freezing, PGT genetic testing, donor egg programs, and male fertility services to underserved add-on clinics increases revenue per patient and diversifies income beyond core IVF cycles.
Shared Embryology and Clinical Staffing Model
Deploying embryologists across sites and recruiting associate REs centrally reduces per-clinic labor costs, improves coverage redundancy, and eliminates single-physician operational risk.
A fertility clinic roll-up targeting 4–6 sites with $6M+ combined EBITDA is positioned for sale to a national platform like US Fertility or Inception Fertility at 7–9x EBITDA, or recapitalization with a larger PE sponsor seeking a proven regional network with contracted employer volume and above-average SART outcomes.
Fertility clinics are SBA-ineligible due to the MSO and Professional Services Agreement structures required to comply with state corporate practice of medicine laws, which prohibit lay entities from directly owning clinical operations.
Physician departure post-close is the primary risk. Patient loyalty follows the RE, not the brand. Locking in multi-year employment agreements with earnouts tied to patient volume before closing is essential protection.
A Management Services Organization owns all non-clinical assets and contracts, while a physician-owned PC retains clinical control. The MSO charges a management fee, capturing economics without violating corporate practice of medicine rules.
A consolidated platform with $6M+ EBITDA, multi-site operations, above-average SART outcomes, and employer benefit contracts typically exits at 7–9x EBITDA to a national strategic acquirer or larger PE sponsor.
More Fertility Clinic Guides
DealFlow OS surfaces off-market platform targets with seller motivation scores. Free to join.
Find platform targets — freeNo credit card required
For Buyers
For Sellers